Trials / Unknown
UnknownNCT03883334
Isoprinosine in HIV Patients With Viral Load > 50 y < 200 Copies/mL
Efecto de la Isoprinosina en Pacientes Con infección Por VIH y Carga Viral Entre > 50 y < 200 Copias/mL de la Unidad de atención de PVV Del Hospital Enrique Garcés en Quito, Ecuador Durante el año 2019.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Universidad San Francisco de Quito · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Virological failure is a complication of treatment in patients with HIV, and it can be as high as 42% to first line treatment or around 18% in second line treatment. The reasons behind this phenomenon are several, including adherence to treatment (self-patient) or those related to the drugs (kinetics, interactions) and the virus itself (resistance patterns). People living with HIV needs treatment for all their lives, another factor to facilitate virus resistance and poor adherence to treatment. For that reason, it is necessary to look for additional therapeutic options to minimize this problem, and the use of immunomodulatory drugs is an interesting topic now. Among those drugs, isoprinosine hs been reported not only improve the immune response, it also has the capability to inhibit the replication of RNA virus. Then, we propose an open label clinical trial to evaluate the effect of isoprinosine in HIV patients with a virological load between 50 and 200 copies/ml.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metisoprinol | Immunodulator |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2020-03-30
- Completion
- 2020-06-30
- First posted
- 2019-03-20
- Last updated
- 2019-12-23
Locations
1 site across 1 country: Ecuador
Source: ClinicalTrials.gov record NCT03883334. Inclusion in this directory is not an endorsement.